Novo Integrated Sciences announced today the successful issuance of a One Billion Dollar gold backed bond, a pivotal development tied to the previously disclosed Master Collateral Transfer Agreement. In the wake of this announcement, stock of Novo Integrated Sciences has experienced a significant surge.
At the time of this publication, Novo Integrated Sciences Inc stock (NVOS) has witnessed a surge.
Novo Integrated Sciences Inc
Current Price: $0.34
Change : +0.08
Change (%): (30.72%)
Volume: 53.0M
Source: Tomorrow Events Market Data
The issuance of the Bond represents the inaugural step in establishing the mechanism for the lawful transfer of collateral, exclusively for the benefit of the Company. This instrument is subject to requisite filings and secure deposit procedures, ensuring authentication and validation for the transfer and utilization of collateral to the advantage of potential lenders.
Robert Mattacchione, CEO and Chairman of the Board at Novo, expressed his enthusiasm, stating, “We are extremely excited at the progress made in securing the collateral transfer facility. This Bond issuance marks a significant step in achieving the funding needed for the Company’s international hypergrowth objectives.”
Novo Integrated Sciences, Inc. is at the forefront of revolutionizing patient-centric health and wellness through a comprehensive healthcare ecosystem comprising services and product innovation. The company aims to deliver, or have the intent to deliver, these services and products by integrating medical technology, advanced therapeutics, and rehabilitative science.
The company believes that decentralizing healthcare, facilitated by the integration of medical technology and interconnectivity, is pivotal in adapting to the rapidly evolving landscape of non-catastrophic healthcare delivery, both presently and in the future. Specifically for non-critical care, ongoing progress in medical technology and interconnectivity allows for a shift in the patient-practitioner dynamic from on-site visits to primary medical centers, towards patient-centric care in the comfort of their own homes. This advancement in accessibility in the patient-practitioner interaction for non-critical care diagnosis and treatment not only reduces the progression of non-critical conditions to critical ones, but also leads to a more cost-effective distribution of healthcare.
Novo’s decentralized healthcare model revolves around three core pillars designed to bolster the transformation of non-catastrophic healthcare delivery to patients and consumers:
First Pillar: Service Networks. This involves providing multidisciplinary primary care services through a network of clinic facilities, including affiliates, small and micro-sized clinics located primarily within commercial enterprises, franchise-operated clinics, and corporate-run facilities.
Second Pillar: Technology. Novo is focused on developing, deploying, and integrating sophisticated interconnected technology that bridges the gap between patient and healthcare practitioner, expanding the reach and availability of the Company’s services beyond traditional clinic locations, reaching areas with limited access to advanced healthcare services.
Third Pillar: Products. Novo aims to develop and distribute personalized health and wellness product solutions, allowing for the customization of patient preventative care remedies and ultimately contributing to a healthier population. The company’s science-driven approach to product innovation emphasizes the creation and provision of over-the-counter preventative and maintenance care solutions.
The fusion of innovation through science with the integration of secure, sophisticated technology positions Novo Integrated Sciences for continued advancement in patient-centric platforms.
